复星医药子公司丁二酸复瑞替尼胶囊药品注册申请获受理

Core Viewpoint - Fosun Pharma's subsidiary, Fosun Wanguo, has submitted a drug registration application for a new drug targeting ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) patients, which has been accepted by the National Medical Products Administration [1] Group 1 - The new drug is an innovative small molecule chemical drug [1] - The application is specifically for the treatment of patients with ALK-positive locally advanced or metastatic NSCLC [1] - Another indication for the drug, targeting ROS1-positive non-small cell lung cancer, has completed Phase II clinical trials in mainland China [1]